---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-048248"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:51:12.149776+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences Q3 revenue $83M, raises FY2025 guidance to $327-335M; launches AdvanceAD-Tx test

## Summary
- Revenue $83.0M (Q3 2025) vs $85.8M YoY; net loss $0.5M vs net income $2.3M.
- Total test reports 26,841; DecisionDx-Melanoma and TissueCypher each exceeded 10,000 tests in a quarter for first time.
- Full-year 2025 revenue guidance raised to $327-335M from $310-320M.
- Launched AdvanceAD-Tx, a GEP test to guide systemic treatment for moderate-to-severe atopic dermatitis.
- Non-dermatologic revenue up 67% YoY; adjusted EBITDA $9.2M vs $21.6M.

## SEC filing metadata
- accession: 0001628280-25-048248
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000162828025048248/0001628280-25-048248-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000162828025048248/cstl-20251103.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-048248
- JSON: https://secwatch.observer/filing/0001628280-25-048248.json
- Plain text: https://secwatch.observer/filing/0001628280-25-048248.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.